EDAP Edap Tms S.A. ADS

EDAP TMS SA to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 30, 2020

EDAP TMS SA to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 30, 2020

Company to host conference call and webcast on Tuesday, March 31st @ 8:30 am EDT

LYON, France, March 24, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2019 after the markets close on Monday, March 30, 2020.

An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chief Executive Officer and François Dietsch, Chief Financial Officer, to review the results. The call will be held at 8:30am EDT on Tuesday, March 31, 2020. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast

Tuesday, March 31st @ 8:30am Eastern Time

Domestic:                    877-451-6152

International:              201-389-0879

Passcode:                    13700921

Webcast:                    

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit -tms.com, and us.hifu-prostate.com.

CONTACTS:

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

50

Investor Contact

Jeremy Feffer

LifeSci Advisors, LLC

212-915-2568

EN
24/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edap Tms S.A. ADS

 PRESS RELEASE

EDAP to Announce Second Quarter 2025 Financial Results on August 28, 2...

EDAP to Announce Second Quarter 2025 Financial Results on August 28, 2025 Company to host conference call and webcast on Thursday, August 28th at 8:30am EDT AUSTIN, Texas, August 7, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the markets open on Thursday, August 28th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and Fran...

 PRESS RELEASE

EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic...

EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer Status Transition to U.S. reporting status to take effect on January 1, 2026 AUSTIN, Texas, July 1, 2025 - EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, announced a change in its U.S. reporting status. EDAP TMS S.A. (the “Company”) currently qualifies as a foreign private issuer under applicable U.S. Securities and Exchange Commission (“SEC”) rules and regulations. Effective January 1, 2026, the Company will no longer qualify for foreign private issuer s...

 PRESS RELEASE

EDAP to Present at the Jefferies Global Healthcare Conference

EDAP to Present at the Jefferies Global Healthcare Conference AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City.  Presentation details: Date:Thursday, June 5th Time:4:20-4:50 PM ET Webcast: The live and archived webcast of the presentation can be accessed in the Investors section of th...

 PRESS RELEASE

EDAP Reports First Quarter 2025 Financial Results

EDAP Reports First Quarter 2025 Financial Results           Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025)Launched the New Focal One i Robotic HIFU System Performed World’s First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global lea...

 PRESS RELEASE

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025 Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch